Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A surge in UnitedHealth Group’s stock on June 27 followed renewed analyst focus on operational progress, the insurer’s long-running dividend growth track record, and a reported new investment in artificial intelligence aimed at lowering costs ahead of a mid-July milestone.
THE APEX TIMES
THE APEX TIMES
At the European Academy of Neurology 2026 Congress, Johnson & Johnson said updated clinical findings for nipocalimab-aahu (IMAAVY) may support earlier use in people with generalized myasthenia gravis, a chronic autoimmune neuromuscular condition.
THE APEX TIMES
The rally, highlighted in a recent market note, has renewed attention on UnitedHealth (UNH) after a period in which some investors appeared to underestimate the pace of improvement.
THE APEX TIMES
Eli Lilly, AbbVie and Johnson & Johnson rose again as investors kept rewarding the large U.S. drugmakers, according to a market report published Tuesday.
THE APEX TIMES
A new market note points to strength in Johnson & Johnson’s drug pipeline and business quality, but argues the stock’s valuation still leaves investors exposed.
THE APEX TIMES
The company said new analyses presented in 12 neurology congress abstracts add to evidence of sustained disease control for IMAAVY in generalized myasthenia gravis, a chronic autoimmune condition.
THE APEX TIMES
Blair Jackson, set to take over at Alkermes, said the next 12 months could be a defining stretch as the company positions itself for the race to develop and commercialize orexin treatments for sleep disorders.
THE APEX TIMES
Moderna shares extended a steep rally Friday, rising roughly 14% to about $68 after setting a new 52-week high during the day. The move is drawing renewed attention to how investors are rotating between vaccine makers such as Merck and Pfizer.
THE APEX TIMES
A recent market round-up framed Bristol Myers Squibb as a specialty-medicine story trading at a discount, while positioning Johnson & Johnson as the steadier cash generator backed by top-tier margins.
